tau rd p301s fret biosensor cell line Search Results


96
ATCC human tau rd p301s fret biosensor
CST levels are reduced across Tauopathies, and AD-spectrum disorders, and CST supplementation suppresses pathological Tau accumulation. CST quantification in human Alzheimer’s disease (AD) cortex shows significantly reduced CST in the (A) prefrontal cortex (PFC) and (C) hippocampus/entorhinal cortex (HC/EC) of Braak VI (n=16) vs. Braak 0–II (n=14) subjects. CST levels positively correlate with Mini-Mental State Examination (MMSE) scores in (B) PFC and (D) HC/EC, linking CST deficiency to cognitive decline. (E&F) Immunostaining of CST in postmortem tissue reveals reduced CST level in Braak VI (n=8) hippocampus compared with Braak 0–II (n=8); quantification shown in ( F ). Scale bar = 100µm (G&H) CST levels are also significantly reduced in cortical tissue from ( G ) corticobasal degeneration (CBD; Braak 0: n=16, Braak 3: n=19) and ( H ) basal ganglia from progressive supranuclear palsy (PSP; Braak 0: n=15, Braak 3: n=19), indicating CST loss as a shared feature of 4R-Tauopathies. (I) In cortical neuron cultures transduced with <t>AAV2–P301S</t> <t>hTau,</t> CST treatment decreases hyperphosphorylated Tau species (S202/T205 and S396/S404) without altering total Tau (n=3). (J–K) Immunocytochemistry confirms CST-mediated suppression of MC1+ misfolded Tau in P301S hTau–expressing neurons; quantified as MC1/MAP2+ area in (n=4). Scale bar = 50µm. (L–N) In organotypic hippocampal slice cultures (OTSC) expressing AAV2–P301S hTau (n=4), ( L ) CST reduces pTau (S202) and pTau (S396/S404) accumulation and ( M&N ) diminishes MC1+ Tau pathology in DG and CA3 regions. Scale bar = 200µm *Data are mean ± SEM; statistical significance indicated as *p < 0.05, **p < 0.01, ***p < 0.001, ***p < 0.0001.
Human Tau Rd P301s Fret Biosensor, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tau+rd+p301s+fret+biosensor+cell+line/bio_rxiv__64898__2026__01__04__697519-383-5-11?v=ATCC
Average 96 stars, based on 1 article reviews
human tau rd p301s fret biosensor - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

95
ATCC tau rd p301s yfp
CST levels are reduced across Tauopathies, and AD-spectrum disorders, and CST supplementation suppresses pathological Tau accumulation. CST quantification in human Alzheimer’s disease (AD) cortex shows significantly reduced CST in the (A) prefrontal cortex (PFC) and (C) hippocampus/entorhinal cortex (HC/EC) of Braak VI (n=16) vs. Braak 0–II (n=14) subjects. CST levels positively correlate with Mini-Mental State Examination (MMSE) scores in (B) PFC and (D) HC/EC, linking CST deficiency to cognitive decline. (E&F) Immunostaining of CST in postmortem tissue reveals reduced CST level in Braak VI (n=8) hippocampus compared with Braak 0–II (n=8); quantification shown in ( F ). Scale bar = 100µm (G&H) CST levels are also significantly reduced in cortical tissue from ( G ) corticobasal degeneration (CBD; Braak 0: n=16, Braak 3: n=19) and ( H ) basal ganglia from progressive supranuclear palsy (PSP; Braak 0: n=15, Braak 3: n=19), indicating CST loss as a shared feature of 4R-Tauopathies. (I) In cortical neuron cultures transduced with <t>AAV2–P301S</t> <t>hTau,</t> CST treatment decreases hyperphosphorylated Tau species (S202/T205 and S396/S404) without altering total Tau (n=3). (J–K) Immunocytochemistry confirms CST-mediated suppression of MC1+ misfolded Tau in P301S hTau–expressing neurons; quantified as MC1/MAP2+ area in (n=4). Scale bar = 50µm. (L–N) In organotypic hippocampal slice cultures (OTSC) expressing AAV2–P301S hTau (n=4), ( L ) CST reduces pTau (S202) and pTau (S396/S404) accumulation and ( M&N ) diminishes MC1+ Tau pathology in DG and CA3 regions. Scale bar = 200µm *Data are mean ± SEM; statistical significance indicated as *p < 0.05, **p < 0.01, ***p < 0.001, ***p < 0.0001.
Tau Rd P301s Yfp, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tau+rd+p301s+fret+biosensor+cell+line/bio_rxiv__267724-47-16-17?v=ATCC
Average 95 stars, based on 1 article reviews
tau rd p301s yfp - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier

Image Search Results


CST levels are reduced across Tauopathies, and AD-spectrum disorders, and CST supplementation suppresses pathological Tau accumulation. CST quantification in human Alzheimer’s disease (AD) cortex shows significantly reduced CST in the (A) prefrontal cortex (PFC) and (C) hippocampus/entorhinal cortex (HC/EC) of Braak VI (n=16) vs. Braak 0–II (n=14) subjects. CST levels positively correlate with Mini-Mental State Examination (MMSE) scores in (B) PFC and (D) HC/EC, linking CST deficiency to cognitive decline. (E&F) Immunostaining of CST in postmortem tissue reveals reduced CST level in Braak VI (n=8) hippocampus compared with Braak 0–II (n=8); quantification shown in ( F ). Scale bar = 100µm (G&H) CST levels are also significantly reduced in cortical tissue from ( G ) corticobasal degeneration (CBD; Braak 0: n=16, Braak 3: n=19) and ( H ) basal ganglia from progressive supranuclear palsy (PSP; Braak 0: n=15, Braak 3: n=19), indicating CST loss as a shared feature of 4R-Tauopathies. (I) In cortical neuron cultures transduced with AAV2–P301S hTau, CST treatment decreases hyperphosphorylated Tau species (S202/T205 and S396/S404) without altering total Tau (n=3). (J–K) Immunocytochemistry confirms CST-mediated suppression of MC1+ misfolded Tau in P301S hTau–expressing neurons; quantified as MC1/MAP2+ area in (n=4). Scale bar = 50µm. (L–N) In organotypic hippocampal slice cultures (OTSC) expressing AAV2–P301S hTau (n=4), ( L ) CST reduces pTau (S202) and pTau (S396/S404) accumulation and ( M&N ) diminishes MC1+ Tau pathology in DG and CA3 regions. Scale bar = 200µm *Data are mean ± SEM; statistical significance indicated as *p < 0.05, **p < 0.01, ***p < 0.001, ***p < 0.0001.

Journal: bioRxiv

Article Title: Catestatin ameliorates tauopathy and amyloidogenesis via adrenergic inhibition

doi: 10.64898/2026.01.04.697519

Figure Lengend Snippet: CST levels are reduced across Tauopathies, and AD-spectrum disorders, and CST supplementation suppresses pathological Tau accumulation. CST quantification in human Alzheimer’s disease (AD) cortex shows significantly reduced CST in the (A) prefrontal cortex (PFC) and (C) hippocampus/entorhinal cortex (HC/EC) of Braak VI (n=16) vs. Braak 0–II (n=14) subjects. CST levels positively correlate with Mini-Mental State Examination (MMSE) scores in (B) PFC and (D) HC/EC, linking CST deficiency to cognitive decline. (E&F) Immunostaining of CST in postmortem tissue reveals reduced CST level in Braak VI (n=8) hippocampus compared with Braak 0–II (n=8); quantification shown in ( F ). Scale bar = 100µm (G&H) CST levels are also significantly reduced in cortical tissue from ( G ) corticobasal degeneration (CBD; Braak 0: n=16, Braak 3: n=19) and ( H ) basal ganglia from progressive supranuclear palsy (PSP; Braak 0: n=15, Braak 3: n=19), indicating CST loss as a shared feature of 4R-Tauopathies. (I) In cortical neuron cultures transduced with AAV2–P301S hTau, CST treatment decreases hyperphosphorylated Tau species (S202/T205 and S396/S404) without altering total Tau (n=3). (J–K) Immunocytochemistry confirms CST-mediated suppression of MC1+ misfolded Tau in P301S hTau–expressing neurons; quantified as MC1/MAP2+ area in (n=4). Scale bar = 50µm. (L–N) In organotypic hippocampal slice cultures (OTSC) expressing AAV2–P301S hTau (n=4), ( L ) CST reduces pTau (S202) and pTau (S396/S404) accumulation and ( M&N ) diminishes MC1+ Tau pathology in DG and CA3 regions. Scale bar = 200µm *Data are mean ± SEM; statistical significance indicated as *p < 0.05, **p < 0.01, ***p < 0.001, ***p < 0.0001.

Article Snippet: HEK 293 cells expressing the human Tau RD P301S FRET biosensor (ATCC CRL-3275) were plated onto Millipore EZ chambered slides at a confluency of 1 × 10 3 cells per well in complete DMEM (DMEM supplemented with 10% Fetal bovine serum and 100μg/mL penicillin-streptomycin).

Techniques: Immunostaining, Transduction, Immunocytochemistry, Expressing

(A) Cortical epinephrine (EPI) levels are markedly elevated in Sal/PS19 compared with nTg controls, and CST treatment significantly lowers EPI concentrations (nTg: n=7, Sal/PS19: n=18, CST/PS19: n=15). (B) Cortical EPI levels are markedly elevated in Sal/5xFAD compared with nTg controls, and CST treatment significantly lowers EPI concentrations (nTg: n=7, Sal/5xFAD: n=6, CST/5xFAD: n=6). (C–E) CST suppresses pathological PKA signaling in the PS19 hippocampus. ( C ) Immunoblots show increased phospho-PKA substrates and elevated p-Tau (S202/T205) in Sal/PS19 mice; CST treatment reduces both, while total Tau and PKA-Cα remain unchanged. ( D&E ) Quantification confirms CST-mediated reduction of PKA activity and Tau phosphorylation (nTg: n=3, Sal/PS19: n=6, CST/PS19: n=5). (F) Schematic illustrating CST blockade ADR–driven PKA activation. In AAV-MAPT (P301S/K18)–transduced hippocampal slices, EPI strongly activates PKA signaling and enhances Tau phosphorylation, whereas CST antagonizes adrenergic/PKA hyperactivation and prevents formation of misfolded Tau species. (G–I) CST counteracts EPI-induced PKA activation and Tau pathology. ( G ) Immunoblot analysis shows that EPI markedly increases phospho-PKA substrates and p-Tau species (S202, S396/404), CST alone has minimal effect on PKA activity. Still, CST prevents EPI-induced PKA hyperactivation (PBS: n=3, CST: n=3, EPI: n=3, CST+EPI: n=3). ( H&I ) Quantification demonstrates CST’s ability to blunt adrenergic/PKA overactivation and its downstream Tau phosphorylation signatures. (J) Immunofluorescence staining (CA3, DG) reveals substantial accumulation of misfolded Tau in EPI-treated slices, which is significantly reduced by CST and nearly abolished by CST+EPI (PBS: n=3, CST: n=3, EPI: n=3, CST+EPI: n=3). Scale bar = 200µM. A.U.: Arbitrary Unit. Data shown as mean ± SEM; significance indicated as *p < 0.05, **p < 0.01, *** p < 0.001, ****p < 0.0001; NS, not significant.

Journal: bioRxiv

Article Title: Catestatin ameliorates tauopathy and amyloidogenesis via adrenergic inhibition

doi: 10.64898/2026.01.04.697519

Figure Lengend Snippet: (A) Cortical epinephrine (EPI) levels are markedly elevated in Sal/PS19 compared with nTg controls, and CST treatment significantly lowers EPI concentrations (nTg: n=7, Sal/PS19: n=18, CST/PS19: n=15). (B) Cortical EPI levels are markedly elevated in Sal/5xFAD compared with nTg controls, and CST treatment significantly lowers EPI concentrations (nTg: n=7, Sal/5xFAD: n=6, CST/5xFAD: n=6). (C–E) CST suppresses pathological PKA signaling in the PS19 hippocampus. ( C ) Immunoblots show increased phospho-PKA substrates and elevated p-Tau (S202/T205) in Sal/PS19 mice; CST treatment reduces both, while total Tau and PKA-Cα remain unchanged. ( D&E ) Quantification confirms CST-mediated reduction of PKA activity and Tau phosphorylation (nTg: n=3, Sal/PS19: n=6, CST/PS19: n=5). (F) Schematic illustrating CST blockade ADR–driven PKA activation. In AAV-MAPT (P301S/K18)–transduced hippocampal slices, EPI strongly activates PKA signaling and enhances Tau phosphorylation, whereas CST antagonizes adrenergic/PKA hyperactivation and prevents formation of misfolded Tau species. (G–I) CST counteracts EPI-induced PKA activation and Tau pathology. ( G ) Immunoblot analysis shows that EPI markedly increases phospho-PKA substrates and p-Tau species (S202, S396/404), CST alone has minimal effect on PKA activity. Still, CST prevents EPI-induced PKA hyperactivation (PBS: n=3, CST: n=3, EPI: n=3, CST+EPI: n=3). ( H&I ) Quantification demonstrates CST’s ability to blunt adrenergic/PKA overactivation and its downstream Tau phosphorylation signatures. (J) Immunofluorescence staining (CA3, DG) reveals substantial accumulation of misfolded Tau in EPI-treated slices, which is significantly reduced by CST and nearly abolished by CST+EPI (PBS: n=3, CST: n=3, EPI: n=3, CST+EPI: n=3). Scale bar = 200µM. A.U.: Arbitrary Unit. Data shown as mean ± SEM; significance indicated as *p < 0.05, **p < 0.01, *** p < 0.001, ****p < 0.0001; NS, not significant.

Article Snippet: HEK 293 cells expressing the human Tau RD P301S FRET biosensor (ATCC CRL-3275) were plated onto Millipore EZ chambered slides at a confluency of 1 × 10 3 cells per well in complete DMEM (DMEM supplemented with 10% Fetal bovine serum and 100μg/mL penicillin-streptomycin).

Techniques: Western Blot, Activity Assay, Phospho-proteomics, Activation Assay, Immunofluorescence, Staining